Regulatory Impact Assessment of Proposed Effluent Guidelines for thePharmaceutical Manufacturing Industry

摘要

The report has been prepared to comply with Executive Order 12866, which requiresfederal agencies to assess the costs and benefits of each significant rule they propose or promulgate. The regulations for the pharmaceutical industry, which are proposed by the U.S. Environmental Protection Agency (EPA, or the Agency), meet the Order's definition of a significant rule. The Agency has assessed both costs and benefits of the proposed rule, as presented in this Regulatory Impact Assessment (RIA).